Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
MEMANTINEHYDROCHLORIDE SAMENSTELLING overeenkomend met ; MEMANTINE ; MEMANTINEHYDROCHLORIDE SAMENSTELLING overeenkomend met ; MEMANTINE ; MEMANTINEHYDROCHLORIDE SAMENSTELLING overeenkomend met ; MEMANTINE ; MEMANTINEHYDROCHLORIDE SAMENSTELLING overeenkomend met ; MEMANTINE
Laboratorio STADA, S.L. Frederic Mompou, 5 08960 SANT JUST DESVERN-BARCELONA (SPANJE)
MEMANTINEHYDROCHLORIDE COMPOSITION in accordance with ; MEMANTINE ; MEMANTINEHYDROCHLORIDE COMPOSITION in accordance with ; MEMANTINE ; MEMANTINEHYDROCHLORIDE COMPOSITION in accordance with ; MEMANTINE ; MEMANTINEHYDROCHLORIDE COMPOSITION in accordance with ; MEMANTINE
Filmomhulde tablet
CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSCARMELLOSE NATRIUM (E 468) ; IJZEROXIDE GEEL (E 172) ; IJZEROXIDE ROOD (E 172) ; IJZEROXIDE ZWART (E 172) ; MACROGOL 3350 ; MAGNESIUMSTEARAAT (E 470b) ; POLYVINYLALCOHOL, GEDEELTELIJK GEHYDROLYSEERD (E1203) ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171)
Oraal gebruik
2020-02-19
1 PACKAGE LEAFLET: INFORMATION FOR THE USER Lonrela 5 mg +10 mg + 15 mg + 20 mg filmomhulde tabletten Memantine hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. Whatis and what it is used for 2. What you need to know before you take Lees het volledige document3. How to take 4. Possible side effects 5. How to store 6. Contents of the pack and other information 1. WHAT IS AND WHAT IT IS USED FOR HOW DOES WORK contains the active substance memantine hydrochloride. belongs to a group of medicines known as anti-dementia medicines. Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory. belongs to a group of medicines called NMDA-receptor antagonists. acts on these NMDA-receptors improving the transmission of nerve signals and the memory. WHAT IS USED FOR is used for the treatment of patients with moderate to severe Alzheimer’s disease. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DO NOT TAKE if you are allergic to memantine hydrochloride or any of the other ingredients of this medicine (listed in section 6) WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking if you have a history
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lonrela 5 mg +10 mg + 15 mg + 20 mg filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg of memantine hydrochloride equivalent to 4.15 mg memantine. Excipient with known effect One film-coated tablets contains 0.27 mg sodium. Each film-coated tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine. Excipient with known effect One film-coated tablets contains 0.55 mg sodium. Each film-coated tablet contains 15 mg of memantine hydrochloride equivalent to 12.46 mg memantine. Excipient with known effect One film-coated tablets contains 0.92 mg sodium. Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine. Excipient with known effect One film-coated tablets contains 1.09 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. The 5 mg film-coated tablets are white, oval, biconvex, 8.1 mm – 4.1 mm, film-coated tablet embossed on one side with ‘5’. The 10 mg film-coated tablets are white, slim through the middle, biconvex, 10 mm – 5.6 mm, film-coated tablet with breaking lines on both sides and engraving ‘1 0’ on one side. The 10 mg tablet can be divided into equal doses. The 15 mg film-coated tablets are light brown, oval, biconvex, 12.3 mm – 6.6 mm, film- coated tablets. The 20 mg film-coated tablets are pink, oval, biconvex, 13.5 mm – 7.3 mm, film-coated tablets. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of patients with moderate to severe Alzheimer’s disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION 2 Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia. Posology Therapy should only be started if a caregiver is available who will regularly monitor the intake of the medicinal product by the patient. Diagnosis should be made according to current guidelines. The tolerance Lees het volledige document